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Abstract
The success of first-line antiretroviral therapy can be
challenged by the acquisition of primary drug resis-
tance. Here we report a case where baseline genotypic
resistance testing detected resistance conferring nucle-
oside/nucleotide  reverse  transcriptase  inhibitor
(nRTI)-associated  mutations,  but  no  primary  muta-
tions for protease inhibitor (PI). subsequent PI-based
HaaRT  with  boosted  saquinavir  led  to  virological
treatment success with persistently undetectable viral
load. after treatment simplification from saquinavir to
an atazanavir based PI-therapy and no change in back-
bone therapy rapid virological breakthrough occurred.
Retrospective analysis displayed preexisting gag cleav-
age site mutations which may have reduced the genetic
barrier  in  a  clinical  relevant  manner  in  combination
with the already existing nRTI resistance mutations.
alternatively, this effect could be explained with a dif-
ferent antiviral potency for the respective PIs used.
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InTRoducTIon
The development of drug resistance is a major con-
cern for successful treatment of human immunodefi-
ciency virus (HIV) infection due to selection of geno-
typic mutations that may lead to reduced phenotypic
drug susceptibility. With common resistance tests mi-
nor  variants  carrying  drug  resistance  mutations  in
HIV,  which  may  emerge  under  antiretroviral  drug
pressure  and  eventually  lead  to  therapy  failure,  may
not be detected. 
large  surveys  have  estimated  that  10  to  25%  of
drug-na￯ve infected patients harbour HIV-1 with mu-
tations for resistance to at least one antiretroviral drug
class [1].
In the area of nordrhein-Westfalen, germany, the
rate of transmitted primary drug resistance mutations
was found to be about 10 % between 2001-2005 [2].
Transmission of drug resistant variants from patients
with resistant viruses takes place in only about 20% to
35% of cases in comparison to drug-sensitive virus.
Recent  estimations  assume  a  lifelong  persistence  of
detectable transmitted drug resistant mutants [3].
drug resistance mutations confer a fitness cost, be-
cause they only occur under drug selection pressure
and do not occur as natural polymorphisms. conse-
quently, the detection rate of viruses with transmitted
resistance mutations is low [4]. nevertheless, highly re-
sistant variants may persist for years in the host [5]. In
chronic HIV infection drug resistance can evolve in
the presence of ongoing viral replication under the se-
lective  pressure  of  antiretroviral  drugs.  frequently,
these acquired drug resistance mutations may reduce
viral  replication  capacity  [6].  Recently,  it  was  shown
that in terms of resistance to protease inhibitors, mu-
tations outside the viral protease can also be selected
during treatment failure and increase the level of resis-
tance.  These  mutations  are  located  in  the  HIV  gag
cleavage sites, which are the natural substrates of the
viral protease during the maturation process leading to
the formation of infectious particles and confer resis-
tance to protease inhibitors by an increased processing
rate of the precursor gag proteins [7]. 
In general, primary genotypic drug resistance in an
antiretroviral-na￯ve patient is recognized as a transmit-
ted infection with HIV strains with mostly single drug
resistance  mutations  in  the  viral  reverse  tanscriptase
and protease. These variants usually display a weak, if
any,  in  culture  measurable  resistance.  It  is  hypothe-
sized that once resistant viruses are transmitted, they
quickly revert most of the mutations to wildtype due
to the impaired fitness of viruses with drug resistance,
thereby explaining why most often only single muta-
tions  but  not  multiple  mutations  are  detected.  as  a
drug  resistance  mutation  usually  occurs  through  ex-
change of one single base pair in a codon, revertance
of such drug resistance cannot be traced. However,
thymidin analogue mutations in codon 215 require a
change of two base pairs to lead to the resistant vari-
ant T215f/y. drug-withdrawal leads to a phenotypical
wild-type (wt) with a different amino acid composition
like  T215d/c/E/l/s.  again  under  antiretroviral
therapy  these  revertants  can  quickly  mutate  back  to
the drug-resistant variant [8]. The acquisition of sever-
al mutations including M41l, d67n, K70R, l210W,
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of resistance to zidovudine and other nRTIs depend-
ing on the particular combination [9].
The detection of resistance mutations and their dif-
ferent interpretation in treatment na￯ve patients com-
pared to therapy experienced patients is essential for
the management of HIV-infected patients. But to date
there is no resistance interpretation tool for therapy
na￯ve patients. 
casE REPoRT
Here we describe the case of a 33-year-old female (W),
first  documented  to  be  human  immunodeficiency
virus type 1 (HIV-1, subtyp B) seropositive in august
2006,  while  presenting  with  pneumocystis  jirovecii
pneumonia and a wasting-syndrom. upon initial pre-
sentation the patient had 60 cd4 cells/ﾵl and more
than 500000 HIV-1 Rna copies/ml (limit of linearity
of the viral load assay Versant bdna, siemens, ger-
many). The patient also reported weakness for the last
year and an episode of herpes zoster for 3 weeks, but
no  test  for  HIV-1  infection  had  been  performed  at
that time. The last negative HIV-test was obtained in
2004. HIV- tests had been performed regularly since
her husband had a documented HIV-infection since
1985, following treatment with blood products he re-
ceived  for  therapy  of  congenital  haemophilia  a
(aXsyM HIV combo, aBBoTT, germany).
genotypic  resistance  testing  identified  M41l  and
T215d as resistance mutations within the reverse tran-
scriptase  and  the  secondary  mutations  I13V,  l63P
within the protease gene regions. Restrospectivly, addi-
tional cleavage site mutations l449V and s451n at the
c-teminal gag cleavage site p1/p6-gag were found.
Table 1 shows the resistance-related mutations de-
tected in the baseline samples as well as those found in
the samples tested later on, according to the Ias resis-
tance panel (www.iasusa.org/resistance_mutations/in-
dex.html).  Resistance  interpretation  systems  like  the
Trugene HIV-1 with guidelines 10.0 were used in these
analyses. 
Highly active antiretroviral therapy (HaaRT) with
tenofovir  (Tdf),  emtricitabin  (fTc)  once  daily  and
saquinavir 1000 mg twice daily boosted by ritonavir
was initiated 2 months after initial HIV-diagnosis in
september 2006. The treatment resulted in a >2-log
decrease in HIV-1 Rna load at week 4, a further de-
cline in viraemia to 56 copies/ml after 3 months of
HaaRT and subsequent complete suppression under
detection  limit  for  19  months  untill  october  2008.
The  cd4  cell  count  in  paralell  increased  to  308
cells/ﾵl and 30%, respectively. during the treatment
period one episode with a blip of 145 copies/ml oc-
curred. In oktober 2008 HaaRT was simplified to
tenofovir,  emtricitabin  and  ritonavir-boosted
atazanavir in order to have a once-daily therapy. With-
in four weeks after initiation of this regimen the viral
load increased to 1381 copies/ml. Viral load decreased
to 132 copies/ml in a control but raised  again to 8515
copies/ml in february 2008.
The virological treatment failure prompted the sec-
ond genotypic drug resistance test which revealed the
same nRTI-associated and gag cleavage site mutations
as  in  the  resistance  test  prior  to  commencing  aRT,
namely M41l and T215d with limited susceptibility
for aZT, d4T and tenofovir (Table 1). The regimen
was changed again in april 2009 to ritonavir boosted
darunavir 800 mg and nevirapine 400 mg once daily.
under the new regimen a skin rash occured six days
after  treatment  initiation.  symptoms  were  regressive
under intake of cortison and vanished after 12 days.
Two months after changing therapy plasma viral load
decreased again below the limit of detection.
The 42 years-old husband (M) having a HIV-infec-
tion since 1985 due to treatment of haemophilia a,
cdc status a2, received his first antiretroviral therapy,
which was aZT-monotherapy, in 1993. In 1995 he was
treated with additional lamivudin (3Tc). a new regi-
men was startet in 1997 with d4T and 3Tc. Because of
lipoatrophy and ongoing viral replication under aRT,
HIV-therapy  was  changed  to  ritonavir-boosted
atazanavir  and  efavirenz  in  2004  after  screening  for
drug  resistance.  genotypic  resistance  testing  in  the
husband showed no nnRTI and no PI mutations but
the  following  nRTI  mutations:  M41l,  M184V  and
T215y.  despite  a  favourable  immunological  respose
under the past antiretroviral therapies, the viral load
became undetectable for the first time in 2005 after
the  switch  to  ritonavir-boosted  atazanavir  and
efavirenz had occurred. cd4 cell counts after chang-
ing  antiretroviral  therapy  remained  stable  with  466
cell/ﾵl (23%). comparing the findings of the geno-
typing  resistance  tests  of  the  infected  couple,  we
found the same resistance mutations in both individu-
als, except for the absence of M184V and the pres-
ence of the “revertant” T215d in place of the T215y
resistance mutation in the HIV infected wife. no resis-
tance mutations could be found in the protease gene
despite virological failure under atazanavir therapy in
the wife but the same two gag cleavage site mutations
(l449V, s451n) remained.
The husband was also coinfected with hepatitis B
and c. Therefore, 3Tc was added to the antiretroviral
therapy for HBV viremia in the same year. HcV infec-
tion was successfully treated with PEg-interferon-al-
pha and weight-based Ribavirin therapy in 2002. no
chronic hepatitis was diagnosed in the wife.
Phylogenetic analysis using a pool of most similar
HIV-1 sequences obtained in the same years from the
same area confirmed that the viruses in these patients
were closer related to each other compared to any oth-
er virus in the local database with a similarity score of
97,5%. (fig.1).
dIscussIon
Here we report the transmission of the thymidine ana-
logue mutations (TaM) T215y and M41l to an anti-
retroviral na￯ve spouse of an HIV-infected haemophil-
iac  patient,  who  subsequently  developed  virological
failure  after  simplifying  her  therapy  to  a  boosted
atazanavir based therapy. The nRTI-resistance muta-
tions M41l and T215y were most likely transmitted
from her husband, who had developed these specific
mutations under a previous phase of aZT monother-
apy in 1993. These TaM mutations are scored by most
of the interpretation systems to confer an intermedi-
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tance to ddI, aBc and Tdf. some interpretations sys-
tems rank Tdf to an intermediate level. one must be
aware  that  the  interpretation  systems  are  developed
for therapy experienced patients and therefore the risk
of the above mentioned resistance mutations is under-
estimated in na￯ves. Phylogenetic analysis clearly indi-
cates a common origin for the viruses and makes it
very  probable  that  transmission  occurred  from  hus-
band to wife.
We  believe,  that  the  transmission  of  the
M41l/T215y mutants were due to aZT administra-
tion in 2004 while M184V occurred under treatment
with  lamivudine.  The  last  negative  HIV-Test  of  the
wife took place in 2004. The T215d-strain occurred as
a revertant from T215y consequently in the absence
of drugs in the wife; T215d is as fit as the wild-type
virus in cell culture assays in the absence of the drug,
but retains the potential for rapid emergence of high-
level zidovudine resistance. T215 d/s/c/E/I/V are
transitions  between  wild  type  virus  and  resistant 
mutants  carrying  y  or  f.  The  presence  of  T215d 
suggests the presence of clinically relevant T215y mi-
norities.
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Table 1. antiretroviral therapy and drug resistance mutation over time in study subjects.
Patient Year Antiretroviral therapy mutations associated with resistance Virus load
Copies/ml




07/2004 RT: M41L, M184V, T215Y, 26929
(T39a, V60I,  d121y,  
I135T,  I142V1, d177g, 
V179I, T200a,  Q207E,  
l214f, l228H, Q334H)
PR: l 63P, I13V, (V3I, K14R, 
s37n)
cs p1/p6-gag: l449V, s451n
08/2004 aTV/r, EfV
01/2005 <50
04/2005 aTV/r, EfV, 3Tc <50
W 08/2006 RT: M41L, T215D, (T39a, V60I, > 500.000
d121y,135T,n137s,I142V,
s162c, I202I/V, Q207E/K, l214f,
l228H)
PR: l63P, I13V, (E35d, s37n/s,
s37n, V3I)
cs p1/p6-gag: l449V, s451n
09/2006 TVd, InV/r




03/2009 RT: M41L, T215D,(T39a,V601I
d121y, K122E,135T,n137s,I142V
s162c, I202IV, Q207E/K, l214f,
l228H, V245M, a272P, T286a, 
E297K)
PR: l63P, I13V, E35d




M = husband/suspected source of infection, W = case-patient
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Fig. 1. The maximum likelihood phylogenetic tree shows the close relationship between patient W and M sequences. Phyloge-
netic analysis was conducted on a data set of 62 HIV-1 polymerase sequences aligned through MutExt and clustalX, including
the four sequences available from patients W and M. The 48 most similar sequences to W03_2009 (01ns–48ns) and 10 per
chance selected sequences (Rs) from patients, obtained from the same geographic area during the same time period, were select-
ed from a total of 6400 sequences in the arevir database (21). Patient W and Patient M sequences are indicated by W and M fol-
lowed by the month and year of the sampling date. HXB2 is the wild type reference strain.
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growth  competition  experiments  in  cell  culture
showed a value of 85% fitness for T215y, 80% for
M41l  and  a  similar  fitness  for  the  double  mutant
M41l/T215y [10, 11] relative to the wildtype in the
absence of drugs. Viruses carrying the T215y muta-
tion emerge more frequently than T215f while show-
ing a faster replication kinetics and greater relative fit-
ness  in  comparison  with  T215f  mutants  in  the  ab-
sence  or  presence  of  zidovudine.  Moreover,  T215y
mutants show greater infectivity than wildtype HIV-1
over a range of aZT concentrations [12]. 
The evaluation of differential transmission of HIV-
1 strains harbouring mutations in RT in newly infected
individuals compared with the prevalence in the po-
tential transmitter population showed that the preva-
lence  of  the  3Tc-resistance  associated  mutation
M184V was only 3%, compared to TaMs 6,7% and
nnRT-associated  mutations  7,4%.  all  this  suggests
that reductions in viral fitness of M184V-containing
HIV-1 strains may partially affect rates of viral trans-
mission [13]. In the absence of therapy the decreased
fitness of viruses carrying T215y/f, K70R, or M184V
is reflected by the pressure to mutate during the evolu-
tion of transmitted HIV-1 resistance mutations [14].
The M184V mutation develops quickly after initiation
of therapy with 3Tc and confers high-level resistance
to this drug and to fTc. aBc and 3Tc are able to
preserve M184V in mixed dual infections consisting of
wildtype viruses and clinical isolates that contain the
M184V mutation [15, 16]. unlike TaMs, M184V re-
verts to wild-type virus when lamivudine is eliminated
from antiretroviral regimens [17]. This mutation con-
fers a low fitness and also reduces the risk of viral
transmission [13], which might explain the absence of
M184V in the wife’s strain. usually in the first period
of infection cd4 T-cell counts remain stable, later the
likelihood of slowly decreasing cd4 T-cell counts in-
creases. The rates were higher in those subjects infect-
ed with resistant viruses with lower replication capaci-
ty [18]. We concluded from the anamnestic data, that
the transmission took place between august 2004 and
January  2005.  under  consideration  of  the  low  cd4
count  at  initial  presentation  a  very  rapid  course  of
HIV-infection needs to be stated. Indeed, the patient
progressed to a cd4 count of 60/ml already 1-2 years
after HIV-1-infection.
Most apparently the therapy failure resulted from
the archieved nRTI resistance for M41l, (probably on
the M184V) and the T215d mutation which was  al-
ready visible in the blood before virological failure oc-
curred  after  switching  from  invirase  to  atazanavir,
both  administered  as  ritonavir-boosted  PIs,  while
tenofovir  and  emtricitabin  remained  unchanged  as
backbone nRTI combination. This further questions
the efficacy of atazanavir in combination with an only
intermediate active nRTI-backbone. adherence prob-
lems or use of proton-pump inhibitors were denied by
the  patient.  The  new  antiretroviral  regimen  with
darunavir/r and nevirapine (2 fully active drugs from 2
divergent drug classes) lead to maximal viral load sup-
pression in less than 8 weeks. The question remains
whether  the  presence  of  mutants  in  sanctuary  sites
carrying M41l, M184V and T215y contributed to the
viral rebound alone or together with effects conferred
by the retrospectively detected gag cleavage site muta-
tions, while PI mutations in the protease gene were
not present. The selection of a PI-based regimen in
case of detection of nRTI mutations is in line with
the European resistance guidelines. nnRTI-based reg-
imens are considered to have a too low genetic barrier
in  first  line  therapy  settings.  on  the  contrary  in  all
first-line  studies,  cases  of  protease  inhibitor  failures
are  described  in  absence  of  detectable  protease  in-
hibitor resistance mutations. In this content, mutations
in  the  gag-region,  the  natural  substrate  of  the  viral
protease,  have  recently  gained  importance  and  has
been shown to contribute directly to protease inhibitor
resistance [7]. Interestingly, the gag cleavage site muta-
tion s451n was classified as a natural polymorphism
[19], whereas cleavage site mutation l449V was found
to  be  significantly  accumulated  in  PI  resistant  HIV
isolates [20]. Therfore, it could be speculated that in
our case study this mutation possibly contributed to
protease inhibitor failure, although the impact of these
gag cleavage site mutations may vary between  differ-
ent PIs. clearly, in this case, the boosted protease in-
hibitors  saquinavir  and  darunavir  were  able  to  sup-
press viral replication with the Tdf/fTc backbone,
whereas  this  was  not  the  case  for  atazanavir/r.  al-
though  recently  drug-resistance  related  mutations  in
the HIV gag-region have been described, their respec-
tive impact on virological treatment failure is not yet
fully understood. Resistance testing is performed rou-
tinely at treatment baseline and some resistance tests
include the sequencing of an important part of gag-
region. But mutations in the gag-region are so far not
considered  in  any  resistance  interpretation  system.
further analyses are required and may lead to routine
resistance testing of the gag-region before starting an-
tiretroviral therapy. 
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